So these investment pros are among those betting on particular U.S. stocks regardless of whether Europe resolves its problems today, tomorrow or whenever.
Unfortunately, federal regulators at the Food and Drug Administration have said they won't approve Clarinex until Schering resolves manufacturing problems at plants in New Jersey and Puerto Rico.